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Basic fibroblast growth factor (bFGF) was recently found to 
modulate the outgrowth-regulating effects of glutamate, and 
protected neurons from several brain regions against exci- 
totoxic/ischemic damage. We provide evidence that the ex- 
citoprotective mechanism of bFGF involves suppression of 
the expression of a 71 kDa NMDA receptor protein (NMDARP- 
71). NMDARP-71 protein and mRNA levels were reduced in 
neurons in bFGF-treated hippocampal cell cultures. The lev- 
els of the NMDARP-7 1 were not reduced by NGF or epidermal 
growth factor, and bFGF did not reduce the level of mRNA 
for the GIuRl kainate/AMPA receptor, demonstrating the 
specificity of the effect of bFGF on the NMDARP-71. The 
reduction in NMDARP-71 expression in bFGF-treated neu- 
rons was correlated with reduced vulnerability to NMDA neu- 
rotoxicity. A major role for NMDARP-71 in calcium responses 
to NMDA and excitotoxicity was demonstrated using anti- 
sense oligonucleotides directed against NMDARP-71. North- 
ern and Western blot analysis and immunocytochemistry 
showed that NMDARP-71 antisense oligonucleotides caused 
a selective suppression of NMDARP-71 mRNA and protein 
levels during 12-44 hr exposure periods. Elevations in in- 
tracellular calcium levels normally caused by glutamate and 
NMDA were attenuated in neurons exposed to NMDARP-71 
antisense oligonucleotide; calcium responses to kainate were 
relatively unaffected. NMDARP-71 antisense oligonucleo- 
tides protected the neurons against excitotoxicity. Thus, 
NMDARP-71 is a necessary component of an NMDA receptor 
mediating calcium responses and neurotoxicity in hippo- 
campal neurons. Taken together, these data identify a mech- 
anism whereby bFGF can modify neuronal responses to glu- 
tamate, and suggest that regulating the expression of 
excitatory amino acid receptors may provide a means for 
growth factors to influence the plasticity and degeneration 
of neural circuits. 
[Key words: antisense oligonucleotide, calcium, excito- 
toxicity, fura-2, growth factors, mRNA, neuronaldeath, NMDA] 
Received June 29, 1992; revised Mar. 11, 1993; accepted Apr. 13, 1993. 
We thank S. Bose, J. Mattson, and Y. Zhang for technical assistance, and Dr. 
J. Geddes for critical comments on this work. We also thank S. Heinemann and 
J. Boulter for supplying us with the GluRl plasmid ~5912 and M. Masu and S. 
Nakanishi for supplying us with the NMDAR 1 plasmid. This work was supported 
by grants to M.P.M. from the NIH (NS29001-01 and AG05144-07) and the 
Alzheimer’s Association and by grants to E.K.M. from AR0 (DAAL03-9 1 -GO 167) 
and NIAAA (AA-47321. 
Correspondence should bc addressed to Dr. Mark Mattson, Sanders-Brown 
Center on Aging, 800 South Limestone, Lexington, KY 40536-0230. 
Copyright 0 1993 Society for Neuroscience 0270-6474/93/134575-14$05.00/O 
Glutamate is the major excitatory neurotransmitter in the mam- 
malian brain (Fonnum, 1984) and receptors for glutamate me- 
diate most higher brain functions including learning and mem- 
ory (Collingridge and Bliss, 1987; Cotman and Iversen, 1987). 
Glutamate receptors are broadly classified into two categories, 
namely, NMDA receptors and non-NMDA receptors. Non- 
NMDA receptors (those responsive to the agonists AMPA, kai- 
nate, quisqualate) mediate routine fast synaptic transmission in 
various cortical and subcortical regions. NMDA receptors, on 
the other hand, may have more specialized roles in neural plas- 
ticity. Thus, in the developing nervous system NMDA receptors 
are involved in the “fine tuning” of synaptic connections (Matt- 
son, 1988; Mattson et al., 1988a,b; Cline and Constantine-Pa- 
ton, 1990; McDonald and Johnston, 1990) and at mature syn- 
apses NMDA receptors are critical to the process of long-term 
potentiation (LTP), a cellular correlate of learning and memory. 
NMDA receptors have the unique property of conducting cal- 
cium ions at a high rate (Mayer and Miller, 1990). Calcium 
influx through the NMDA receptor is essential for LTP (Malen- 
ka et al., 1988). Ironically, the calcium-conducting property of 
NMDA receptors can prove detrimental to neurons, as overacti- 
vation of NMDA receptors can result in neuritic degeneration 
and cell death (Rothman and Olney, 1987; Choi, 1988; Mattson, 
1992). Ample evidence supports the involvement of NMDA 
receptors in the neuronal damage that occurs in stroke, epilepsy, 
and Alzheimer’s disease (for reviews, see Siesjo et al., 1989; 
Greenamyre and Young, 1989; Mattson, 1992). 
Within the last three years, several glutamate receptor pro- 
teins have been identified and characterized at the molecular 
level. A family of AMPA/kainate receptor proteins that has been 
cloned (Hollmann et al., 1989; Boulter et al., 1990) apparently 
combines in various permutations to form multisubunit recep- 
tors. Recently, a putative NMDA receptor protein complex was 
isolated from rat brain synaptic membranes (Ikin et al., 1990; 
Kumar et al., 199 1; Ly and Michaelis, 199 1) and the cDNA for 
a 71 kDa subunit of this complex (NMDARP-71) was cloned 
(Kumar et al., 199 1). Protein reconstitution and pharmacolog- 
ical studies suggest hat NMDARP-7 1 is the glutamate-binding 
subunit of a complex of four proteins that comprise a functional 
NMDA receptor-ion channel (Kumar et al., 1991; Ly and Mi- 
chaelis, 199 1; Minami et al., 199 1). The latter conclusion is 
consistent with molecular characterizations of the NMDA re- 
ceptor through the use of conotoxins, as well as electrophysio- 
logical characterization of the NMDA receptor (Ascher and No- 
wak, 1987; Clements and Westbrook, 199 1). NMDARP-7 1 was 
shown to be localized to postsynaptic sites in hippocampus in 
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viva (Eaton et al., 1990) and to dendrosomatic compartments 
in hippocampal pyramidal-like neurons in cell culture (Mattson 
et al., 1991). A strong correlation between the presence of 
NMDARP-7 1 immunoreactivity and vulnerability to glutamate 
neurotoxicity was established (Mattson et al., 199 1). 
In addition to NMDARP-7 1, the cDNA for a single protein 
of approximately 100 kDa that possesses electrophysiological 
properties of an NMDA receptor when expressed in frog oocytes 
was also cloned (Moriyoshi et al., 1991; Yamazaki et al., 1992). 
The latter protein, referred to as NMDARl, has not been pu- 
rified, but its structure is inferred from the cloned cDNA and 
exhibits considerable homology to the kainate/AMPA receptor 
family (Hollman et al., 1989; Boulter et al., 1990; Keinanen et 
al., 1990). Several homologs of NMDAR 1 were recently cloned 
also and shown to form functional receptor complexes with 
NMDARl (Monyer et al., 1992). The NMDARP-71 subunit 
does not have such homology to the 100 kDa glutamate receptor 
proteins (Kumar et al., 199 1). The role of the NMDARl or the 
homologs NMDAR2A-C in neurons has not been defined. It is 
now essential to establish which NMDA receptor proteins are 
normally functional and mediate the calcium influx that un- 
derlies roles of NMDA receptors in neural plasticity and de- 
generation. In the present study, antisense oligonucleotides di- 
rected against the NMDARP-7 1 were used to establish roles for 
this protein in NMDA-induced calcium influx and neurotoxicity 
in hippocampal neurons. 
An increasing number of growth factors are being identified 
that influence neuronal survival and plasticity. Among neuronal 
growth factors, NGF and basic fibroblast growth factor (bFGF) 
have been the most intensively studied. Both NGF and bFGF 
have been shown to influence the outgrowth and survival of 
developing neurons from specific regions of the CNS; bFGF 
may have a much broader array of neural targets than does NGF 
(see Hefti et al., 1989, for review). In addition to influencing 
the development and plasticity of neural circuits, growth factors 
may play roles in protecting neurons in a variety of neurode- 
generative conditions. For example, bFGF and NGF can protect 
neurons in cell culture (Cheng and Mattson, 199 1) and animal 
models of ischemia (Berlove et al., 199 1; Shigeno et al., 199 1). 
These growth factors may also play a neuroprotective role in 
more chronic neurodegenerative disorders such as Alzheimer’s 
disease (Hefti et al., 1989; Cheng and Mattson, 1992a). The 
mechanisms of action of growth factors in protecting neurons 
against environmental insults are not clear. 
In earlier studies, we found that bFGF could protect cultured 
rat hippocampal neurons against glutamate neurotoxicity (Matt- 
son et al., 1989) and hypoglycemic damage (Cheng and Mattson, 
199 1). In the present study we explored the possibility that the 
mechanism of the excitoprotective action of bFGF may be 
through regulation of gene expression of NMDARP-7 1. Because 
of the availability of highly specific monoclonal antibodies against 
the NMDARP-71, the regulation of expression of this protein 
in neurons in response to bFGF could be directly examined. 
Exposure of neurons to bFGF reduced the levels of NMDARP- 
7 1 mRNA and proteins, and reduced neuronal vulnerability to 
excitotoxicity. 
Materials and Methods 
Cell culture. Procedures for dissociated cell culture of embryonic day 
18 rat hippocampus are detailed in our previous reports (Mattson et 
al., 1988a, 1991). Cultures were plated at a low cell density (70-120 
cells/mm* of culture surface), and were maintained in a medium con- 
sisting of Eagle’s minimum essential medium (MEM) supplemented 
10% with fetal bovine serum and containing 1 mM pyruvate and 20 mM 
KC1 (0.8 ml/35 mm culture dish). For antisense oligonucleotide exper- 
imenis cultures were maintained in a defined medium consisting of 
Eaele’s MEM sunnlemented with 5 &ml bovine insulin, 100 wn/rnl 
h&an transfer& 100 &ml BSA (fiaition V), 60 @ml p;ogest&ne, 
16 &ml putrescine, 40 @ml sodium selenite, 42 rig/ml thyroxine, 33 
rig/ml tri-iodo+thyronine, 1 mM pyruvate, and 20 mM KC1 (all from 
Sigma). In some experiments cultures were maintained in defined me- 
dium from culture day 1 onward. Glial proliferation was greatly reduced 
in the cultures maintained in defined medium as compared to serum- 
containing medium. At the time of experimentation (culture days 6- 
14), non-neuronal cells constituted 1 O-30% and less than 2% of the total 
number of cells in the cultures maintained in serum-supplemented and 
defined medium, respectively. Cultures were maintained in an atmo- 
sphere containing 6% CO,, 94% room air (37°C). 
Oligonucleotides. Oligonucleotides were synthesized by the Univer- 
sity of Kentucky molecular biology facility using an Applied Biosystems 
380B synthesizer. Oligonucleotides were purified using reverse-phase 
Cl 8 Sep-Pak cartridges (Waters). Oligonucleotide stocks were prepared 
in sterile water at concentrations of l-2 mM. The oligonucleotides used 
in the present study included NMDARP-71 (Kumar et al., 1991) an- 
tisense 1 (AS l), 5’-GAGGGCTGGAAAGCGGCCTGT-3’; NMDARP- 
7 1 antisense 2 (AS2), 5’-GAAACTCTTTTCATGGTACA-3’; 
NMDARP-7 1 sense, 5’-ACAGGCCGCTTTCCAGCCCTC-3’. All ex- 
periments involving oligonucleotides were carried out in cultures con- 
taining defined medium (composition is given above). 
Experimental treatment of cultures and analysis of neuronal survival. 
L-Glutamate, NMDA, kainate, quisqualate, and aminophosphonovale- 
ric acid (APV, Sigma) were prepared as 100-500x stocks in culture 
medium (pH 7.2). Basic FGF (bovine recombinant), NGF (2.5s from 
mouse submaxillary glands), and epidennal growth factor (EGF, from 
mouse submaxillary glands) were purchased from Boehringer Mann- 
heim and were prepared as 500x stocks in cultured medium. Unless 
otherwise stated, growth factors were added on culture day 3 and oli- 
gonucleotides were added on culture day 6. Basic FGF (10 &ml) was 
added to cultures 24 hr prior to the addition of excitatory amino acids 
(EAAs). Neuronal survival was assessed by phase-contrast light mi- 
croscopy as described previously (Mattson et al., 1988a, 199 1). Briefly, 
neurites that normally are uniform in diameter and smooth in appear- 
ance become fragmented and “beaded” during the degenerative process. 
In addition, the soma, which is normally smooth and round to oval in 
shape, becomes rough, vacuolated, and irregular in shape in degener- 
ating neurons. Viable neurons in premarked microscope fields (each 
field was approximately 1 mm2) were counted prior to and 8 hr 
following exposure to EAAs. 
Immunocytochemistry. These methods were similar to those previ- 
ously reported (Mattson et al., 1991). Cells were fixed for 20-30 min 
in cold fixative that consisted of a solution of 2% paraformaldehyde, 
100 mM D,L-lysine, 10 mM sodium m-periodate, and 0.5% glutaralde- 
hyde in 0.1 M phosphate-buffered saline (PBS). Cell membranes were 
permeabilized by exposure to a 0.2% solution of Triton X-100 in PBS 
for 5 min. Cells were then incubated for 30 min in the presence of 
blocking serum (nonimmune horse serum, 1:200), followed by a 3 hr 
incubation in PBS containing the primary antibody. Two monoclonal 
antibodies against the NMDARP-7 1 isolated from rat or bovine brain 
(clones 27GLE,,, IgM, and 17G,,C,, IgG, respectively) were used at a 
dilution of 1: 10. Following incubation for 3 hr in the presence of the 
primary antibody, the cultures were processed using a Vector Labs ABC 
kit with goat anti-mouse biotinylated secondary antibody, avidin-per- 
oxidase complex, and diaminobenzidine tetrahydrochloride. Possible 
nonspecific staining was evaluated by eliminating the primary antibody 
from the staining procedure, or preabsorbing the primary antibody with 
a threefold excess of purified antigen (NMDARP-7 1). The NMDARP- 
71 was purified from rat brain synaptic membranes according to the 
procedure described in Wang et al. (1992). Western blots performed 
with this purified protein and monoclonal antibodies that were pread- 
sorbed with a threefold excess of NMDARP-7 1 produced no detectable 
labeling of this protein by the antibodies. The same exposure conditions 
were used to photograph all cells, and photographic prints were exposed 
for the same time periods. Comparisons of neuronal immunoreactivity 
were made by scoring the staining intensity of individual neurons on a 
scale from 0 to 3 (0, no staining; 1, light; 2, moderate; 3, heavy). Cultures 
were scored without knowledge of their treatment history. A total of 
400 neurons were scored in four separate cultures (100 neurons/culture). 
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Western blot analysis. These methods are detailed elsewhere (Mattson 
et al., 1991). Proteins from untreated control cultures, and cultures 
treated with oligonucleotides or growth factors were separated on 10% 
SDS-PAGE and electrotransferred to nitrocellulose filters. The nitro- 
cellulose sheets were reacted with NMDARP-7 1 antibody 27G,E, I (IgM) 
(hybridoma culture supematant). This was followed by incubation with 
alkaline phosphatase-conjugated goat anti-mouse IgM antibodies in 
order to reveal the immunolabeled proteins. The relative amount of 
immune reaction products formed on Western blots was measured by 
image analysis procedures using a Universal Imaging System (Balazs et 
al., 1992). The protein concentration of cell homogenate samples was 
estimated by the BCA method (Pierce Chemical). 
Northern blot analysis. Hippocampal neurons were cultured as de- 
scribed above, including exposure to oligonucleotides and growth fac- 
tors. Each population of RNA was prepared by the guanidine iso- 
thiocyanate-cesium chloride purification method. Total RNA was 
size-fractionated on a 1% formaldehyde-agarose gel and transferred to 
Nytran (MSI) membranes. A 550 base pair (bp) Pst 1 restriction frag- 
ment of DGBA-2 MMDARP-71 cDNA). a 570 bn Pst 1 fraament of 
the cDNA clone ‘p59/2 for GluRl, and the full-length cDNA for 
NMDARl were purified by extracting from low-melting-temperature 
agarose gels and labeled with 32P-dATP by the random primer labeling 
method (total activity of 5.2 x lo8 dpm in 15 ml hybridization buffer). 
These probes were hybridized to the RNA blot. RNA concentrations 
were estimated by measuring absorbance ratios at 260:280 nm. The 
specific amounts of RNA introduced into each lane are indicated in the 
figure captions. Agarose gels stained with ethidium bromide were also 
examined to determine equal loading with RNA. Prehybridization was 
carried out at 42°C for 3 hr in 5 x SSPE (1 x = 0.18 M NaCl, 10 mM 
sodium phosphate, 1 mM EDTA), 5 x Denhardt’s solution (1 x = 0.02% 
ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin), 0.1% 
SDS, and 50 &ml of denatured salmon sperm DNA. Hybridization 
was done at 42°C for 16 hr in the same buffer that included 50% form- 
amide. Filters were washed with 1 x SSPE, 0.5% SDS at 37°C followed 
bv 0.1 x SSPE. 0.1% SDS at 65°C. The filters were exnosed to Kodak 
X-Omat film with an intensifying screen for 48 hr. Therelative amount 
of RNA labeled by the various probes was quantified by image analysis 
procedures similar to those used for Western blot analyses. The filters 
were then stripped and probed with a 27-mer rat p-actin oligonucleotide 
(Clontech), which was used as a control probe, and the autoradiograms 
obtained were subjected to image analysis. 
Measurements of intracellular free calcium levels. Fluorescence ratio 
imaging of the calcium indicator dye fura- was used to quantify intra- 
cellular free calcium levels in the cultured hippocampal neurons. The 
methods used were identical to those used in our past studies (Mattson 
et al., 1989; Cheng and Mattson, 1991). Briefly, cells were loaded for 
30 min with a 24 PM concentration of the acetoxymethylester form of 
fura-2. The cells were then washed and incubated an additional 1 hr. 
Prior to imaging the culture maintenance medium was replaced with a 
medium consisting of Hanks’ balanced salt solution (HBSS) containing 
10 mM HEPES, 20 mM glucose, and 2 mM CaCl,. Cells were imaged 
with epifluorescent illumination (xenon UV source) with an inverted 
Nikon Diaphot microscope (fluoro 40 x , 1.3 NA fluorescence objective) 
coupled to an intensified CCD camera (Quantex), and a Quantex im- 
aging system equipped with QFM software. Intracellular Ca2+ levels were 
determined from the ratio of the fluorescence emission using two dif- 
ferent excitation wavelengths (350 nm and 380 nm). Background flu- 
orescence at each wavelength (background images were taken from regions 
of the culture dish not containing cells) was subtracted from the cell 
image at that wavelength. The system was calibrated according to the 
orocedures of Grvnkiewicz et al. (1985) usina the formula ICal. = KJR 
- RnmYRn,x - k)](F,/F,). For our system,>,,, = 0.98, i,,,,:= 10140, 
F,IF, = 13.99, and Kd = 224.0. Values represent the average free calcium 
level in the neuronal cell body. Statistical comparisons were made using 
Student’s t tests. 
Results 
bFGF reduces NMDARP-71 protein levels in cultured 
hippocarnpal neurons 
Levels of NMDARP-7 1 immunoreactivity were markedly re- 
duced in cultures maintained for 0.5-4 d in the presence of 10 
&ml of bFGF (Fig. 1). Staining was reduced progressively over 
a period of 1248 hr of exposure to bFGF, and remained low 
through at least 4 d of exposure. After 2 d of exposure, average 
neuronal staining intensities were 1.98 f 0.06 in control cultures 
and 0.56 f 0.05 in bFGF-treated cultures (n = 400 neurons in 
four separate cultures; p < 0.001; see Materials and Methods). 
Neuronal NMDARP-7 1 immunoreactivity was not changed in 
cultures maintained for 2 d in the presence of 10 rig/ml of either 
NGF or EGF (n = 4 separate cultures). The reduction in 
NMDARP-7 1 immunoreactivity caused by bFGF apparently 
resulted from a direct action of bFGF on neurons since bFGF 
also reduced NMDARP immunoreactivity in cultures main- 
tained in a completely defined medium in which less than 2% 
of the cells in the cultures were non-neuronal (see Materials and 
Methods). Under the latter conditions bFGF did not signifi- 
cantly affect astrocyte numbers during a 2 d exposure period 
(astrocyte density was 1.2 f 0.2l/mm* of culture surface in 
control cultures and 1.5 f 2.3/mm2 in bFGF-treated cultures; 
n = 5 separate cultures). The bFGF-induced reduction in 
NMDARP-71 levels was confirmed by Western blot analyses 
of cultured cell homogenates (Fig. 2). Gels were loaded with 
equivalent amounts of protein from cell cultures exposed for 4 
d to 10 &ml of bFGF, NGF, EGF, or no growth factor. Our 
previous dose-response studies showed that bFGF and NGF at 
10 rig/ml were maximally effective in protecting cultured hip- 
pocampal neurons against hypoglycemic damage, while EGF 
was ineffective at this concentration (Cheng and Mattson, 199 1). 
Immunoblots with a monoclonal NMDARP-7 1 antibody dem- 
onstrated a clear decrease in the expression of the 71 kDa 
NMDARP-7 1 in bFGF-treated cultures compared with untreat- 
ed control cultures (Fig. 2). Other bands in Coomassie blue- 
stained gels were not changed by bFGF (data not shown), sug- 
gesting that the actions of bFGF were specific. In lanes that were 
loaded with 60 pg of solubilized cell proteins, there is the ap- 
pearance of a second band of protein (60-63 kDa) labeled by 
the antibodies. This band of protein is probably the result of 
protein breakdown as was discussed in a previous publication 
(Eaton et al., 1990). NGF and EGF did not influence the levels 
of immunolabeled NMDARP-71 on Western blots (Fig. 2). In 
addition, levels of NMDARP-71 immunoreactivity were re- 
duced by bFGF in neuron-enriched cultures in which glial pro- 
liferation was blocked by incubation in a defined medium lack- 
ing serum. Average neuronal staining intensities were, for 
untreated control culture, 2.10; culture treated for 2 d with 10 
rig/ml bFGF, 1.27; culture treated for 2 d with 10 r&ml NGF, 
1.96; and culture treated for 2 d with 10 rig/ml EGF, 1.87 (n = 
100 neurons scored for each treatment condition). No immu- 
nolabeling of cells or isolated proteins was seen in immunocy- 
tochemistry or Western blots when nonimmune mouse im- 
munoglobulins were used as primary antibodies (data not shown). 
In addition, preabsorption of the primary antibody with excess 
purified NMDARP-7 1 abolished neuronal staining (see Fig. 7). 
bFGF reduces levels of mRNA encoding NMDARP- 71 
The decrease in levels of NMDARP-7 1 in neurons treated with 
bFGF may have resulted from an effect of this growth factor on 
protein synthesis or degradation. In order to determine whether 
bFGF affected the expression of mRNA for the NMDARP-7 1, 
we analyzed the levels of NMDARP-7 1 mRNA in control and 
bFGF-treated hippocampal cultures. The Northern blots shown 
in Figure 3 demonstrate that the effect of a 4 d exposure of 
cultured hippocampal neurons to bFGF is a decrease in the level 
of mRNA that hybridizes with the NMDARP-71 probe. The 
1.8 kilobase (kb) RNA species labeled in cultured hippocampal 
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Figure 1. bFGF reduces the level of NMDARP-7 1 immunoreactivity in hippocampal cell cultures. Neuronal NMDARP-7 1 immunoreactivity in 
an untreated 6-d-old culture is intense (A). Neuronal NMDARP-7 1 immunoreactivity in a 6-d-old culture to which bFGF (10 &ml) was added 
on culture days 4 and 5 is markedly reduced (B). Numbers adjacent o neurons indicate staining intensity on a relative scale: 0, no staining; 1, light; 
2, moderate; 3, intense. g, &al cell. These results are representative of those obtained in eight separate control and bFGF-treated cultures. Scale 
bar, 10 pm. 
neurons appears to be identical to that labeled in RNA extracted 
from whole rat brain (Fig. 3) or from various brain regions 
(Kumar et al., 1991). The effect of bFGF on the RNA for the 
NMDARP-71 appears to be very selective, as RNA from the 
same cells labeled with a cDNA probe for GluR 1, the clone for 
the 100 kDa kainate/AMPA receptor (Hollman et al., 1989; 
Keinanen et al., 1990) was not decreased in bFGF-treated neu- 
rons (Fig. 3). Densitometric analysis of Northern blots dem- 
onstrated a time-dependent reduction in NMDARP-7 1 mRNA 
levels in bFGF-treated cultures (Fig. 4). NMDARP-7 1 mRNA 
levels were reduced to 9 1% and 73% of control levels within 24 
and 48 hr of exposure to bFGF, respectively, and continued to 
decrease to 2 1% of control levels after 4 d of exposure. The data 
shown in Figures 3 and 4 were derived from three separate 
experiments, each Northern blot analysis performed at least 
twice. 
bFGF protects neurons against excitotoxicity 
We previously reported that bFGF protected cultured hippo- 
campal neurons against glutamate neurotoxicity (Mattson et al., 
1989), but we did not establish whether the protection was 
specific for activation of a particular class of EAA receptor. In 
the present study we examined whether the protective effect of 
bFGF was specific for NMDA-induced excitotoxicity. Neuronal 
survival in cultures exposed to NMDA was significantly en- 
hanced in cultures maintained in the presence of bFGF (Fig. 5). 
In addition, calcium responses to NMDA (measured using flu- 
orescence ratio imaging of the calcium indicator dye fura-2) were 
reduced in bFGF-treated neurons (data not shown; cf. Mattson 
et al., 1989). Thus, the reduced expression of NMDARP-7 1 was 
reflected in reduced neuronal vulnerability to NMDA neuro- 
toxicity. Neuronal survival in cultures exposed to kainate or 
quisqualate was also significantly enhanced by bFGF, suggesting 
that bFGF might also influence the expression or function of 
non-NMDA receptors. On the other hand, the Northern blot 
analysis above indicated that kainate/AMPA GluRl receptor 
levels were not reduced by bFGF. In order to resolve this prob- 
lem, we tested the hypothesis that the reduced vulnerability to 
kainate and quisqualate in bFGF-treated cultures resulted from 
reduced expression of NMDA receptors. This possibility was 
suggested by the results of recent studies demonstrating that 
activation of non-NMDA receptors, which results in membrane 
depolarization, can induce glutamate release from the cells, which 
then activates NMDA receptors (Sucher et al., 1991). Hippo- 
campal cultures incubated in the presence of the NMDA recep- 
tor antagonist APV were exposed to kainate or quisqualate and 
neuronal survival in these cultures was compared to that in 
cultures exposed to the agonists in the absence of APV. APV 
significantly reduced neuronal death in cultures exposed to kai- 
nate or quisqualate (Fig. S), indicating that the neurotoxicities 
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Figure 2. Western blot analysis of NMDARP-7 1 in growth factor-treated cultures. Lanes 14 in A-C represent proteins from cultures treated for 
4 d with EGF, NGF, bFGF, and an untreated culture, respectively. Solubilized proteins (60, 40, and 20 rep) were loaded into each lane in A-C, 
respectively. Note that bFGF reduced the level of NMDARP-7 I-immunoreactive band in all three cases. These results are representative of those 
obtained in three separate experiments. 
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Figure 3. bFGF causes a selective de- 
crease in levels of mRNA for the 
NMDARP-71. Shown are Northern 
blots using restriction fragments of the 
cDNAs for the NMDARP-7 1 (pGBA- 
2; Kumar et al., 199 1) and the kainatel 
AMPA receptor (GluR 1; Hollman et al., 
1989; Keinanen et al., 1990). RNA was 
prepared from either whole rat brain or 
rat hippocampal cell cultures that either 
were not treated (control) or were treat- 
ed with 10 rig/ml bFGF for 4 d. The 
amounts of RNA loaded into each lane 
are indicated at the bottom. The results 
of Northern hybridization with pGBA-2 
are shown in A; those with GluRl are 
in B. Note that bFGF caused a reduc- 
tion in the level of mRNA for 
NMDARP-7 1 but did not decrease the 
level of GluRl mRNA. 





Figure 4. Time course of reduction in NMDARP-7 1 mRNA levels in 
cultures exposed to bFGF. Parallel hippocampal cell cultures were un- 
treated (control) or were exposed to 10 @ml bFGF for the indicated 
number of days. NMDARP-7 1 mRNA levels were quantified by den- 
sitometric analysis of the 1.8 kb RNA species on Northern blots probed 
with the Pstl Fragment of pGBA-2. The levels for the treated cultures 
are expressed as percentage of the respective control culture. In each 
case, 15 pg of RNA was loaded onto each lane. 
of these agonists were mediated, at least in part, via NMDA 
receptors. 
We previously demonstrated that neurons contacting glia in 
hippocampal cultures were protected against glutamate neuro- 
toxicity and that astrocyte-derived bFGF played a role in this 
excitoprotective action (Mattson and Rychlik, 1990). Taken to- 
gether with the data above, the latter observation suggested that 
neurons contacting glia should exhibit reduced levels of 
NMDARP-7 1. This possibility was tested by comparing levels 
of NMDARP-71 immunoreactivity in neurons contacting as- 
trocytes with those not contacting astrocytes (essentially all of 
the non-neuronal cells in these cultures were immunoreactive 
toward glial fibrillary acidic protein antibodies and were there- 
fore presumed to be type I astrocytes; cf. Mattson et al., 1988a; 
100 
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NMDA Kainate Quisqualate 
?GF protects against NMDA receptor-mediated neuro- 
toxicity in hippocampal cell cultures. Hippocampal cells (6 d in culture) 
were exposed to the indicated EAA agonists and/or antagonists for 8 
hr and the percentage of neurons surviving the exposure period was 
determined. Values represent he mean and SEM of determinations 
made in four separate cultures. *, significant difference from control 
value (p < 0.01 for NMDA and kainate; p < 0.05 for quisqualate; 
paired Student’s t test). 
Mattson and Rychlik, 1990). NMDARP-7 1 immunoreactivity 
was significantly less in neurons contacting astrocytes as com- 
pared to neurons not contacting astrocytes (average staining 
intensity of 0.98 + 0.32 in neurons contacting an astrocyte and 
2.28 + 0.09 in neurons not contacting an astrocyte; mean f 
SEM of determinations made in four separate cultures with 100 
neurons scored/culture; t = 12.9, p < 0.00 1, Student’s t test). 
An example of reduced NMDARP-7 1 immunoreactivity in neu- 
rons contacting astrocytes is shown in Figure 6. In some ex- 
periments cultures were exposed to glutamate for 8 hr and then 
immunostained with NMDARP-71 antibodies. In such cul- 
tures, neurons contacting astrocytes were protected against glu- 
tamate toxicity and generally showed low levels of NMDARP- 
71 immunoreactivity. As previously described (Mattson and 
Rychlik, 1990), neurons not contacting astrocytes were more 
vulnerable to excitotoxicity, and stained more intensely with 
NMDARP-7 1 antibodies (Fig. 6). These data are consistent with 
our previous work in which a correlation between expression 
of NMDARP-7 1 and vulnerability to excitotoxicity was estab- 
lished (Mattson et al., 1991). In order to probe more directly 
the relationship between NMDARP-7 1 and the vulnerability of 
hippocampal neurons to excitotoxicity elicited by NMDA, we 
utilized the approach of pretreating neurons with antisense oli- 
gonucleotides to the NMDARP-7 1 to block selectively the ex- 
pression of this protein. 
NMDARP-71 receptor protein and mRNA levels are reduced 
in neurons exposed to antisense oligonucleotides 
Hippocampal cell cultures either were left untreated or were 
exposed to a 10-50 PM concentration of NMDARP-71 sense, 
antisense 1 (ASl), or antisense 2 (AS2) oligonucleotide. Cul- 
tures were fixed at 12, 20, and 44 hr following treatment, and 
were immunostained using monoclonal antibodies to NMDARP- 
7 1 (Mattson et al., 199 1). The neuronal immunoreactivity was 
eliminated by absorption of the primary antibody with excess 
NMDARP-7 1 protein (Fig. 7). NMDARP-7 1 immunoreactiv- 
ity was greatly reduced in cultures exposed to AS1 or AS2 for 
12-20 hr relative to untreated cultures or cultures exposed to 
NMDARP-71 sense DNA (Figs. 7, 8). The greatest reduction 
in NMDARP-71 immunoreactivity was observed in cultures 
exposed for 20 hr to AS1 and AS2 (50 PM), and levels of im- 
munoreactivity subsequently increased between 20 and 44 hr 
of exposure. The effects of AS1 and AS2 were concentration 
dependent, as a greater reduction in immunoreactivity was ob- 
served following a 20 hr exposure to 50 I.IM NMDARP-7 1 AS1 
or AS2 than in parallel cultures exposed to 10 PM NMDARP- 
7 1 AS 1 or AS2 (Fig. 8). 
Western blot analyses of proteins extracted from cultures ex- 
posed to sense or antisense oligonucleotides for 22 hr confirmed 
that a reduction in levels of NMDARP-7 1 did, in fact, occur in 
cultures exposed to NMDARP-7 1 antisense oligonucleotide (Fig. 
9). The levels of NMDARP-7 1 in untreated cultures were nearly 
identical to those in cultures exposed to sense NMDARP-71 
oligonucleotide. Treatment of these primary neuronal cultures 
with NMDARP-71 antisense oligonucleotide brought about a 
48% decrease in the levels of NMDARP-7 1 detected on Western 
blots by image analysis. Northern blot analysis revealed that 
treatment of the cultures with NMDARP-71 antisense oligo- 
nucleotide also reduced levels of mRNA for NMDARP-71. 
NMDARP-71 mRNA levels were reduced to 80% of control 
within 12 hr of exposure to NMDARP-7 1 AS 1 and continued 
to decline to 62% of control after 20 hr of exposure (Fig. 10). 
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Figure 6. Neurons contacting astroeytes exhibit reduced NMDARP-7 1 immunoreactivity and reduced vulnerability to glutamate neurotoxicity: 
phase-contrast (left) and bright field (right) micrographs of a field of cultured bippocampal cells exposed to 500 PM glutamate for 8 br and then 
immunostained with NMDARP-7 1 antibody. The two neurons contacting the astrocyte (A; top) were resistant (r) to glutamate neurotoxieity and 
exhibited a very low level of NMDARP-7 1 immunoreactivity. In contrast, the neurons not contacting astrocytes (bottom) were vulnerable (v) to 
glutamate toxicity (note fragmented neurites and irregular somata) and exhibited considerable NMDARP-71 immunoreactivity. Scale bar, 10 lrn. 
The effects of the NMDARP-7 1 antisense oligonucleotides were 
specific in that levels of mRNA for both the NMDARl and 
GluRl were unaffected by NMDARP-7 1 antisense oligonu- 
cleotides (levels for these two mRNA species remained at 98- 
104% of control following 12 to 20 hr exposure to ASI). Fur- 
thermore, mRNA levels for /3-actin remained at 100% of control 
following similar treatment of these cultures, an indication of 
equal loading of RNA across different lanes. 
Calcium responses to NMDA are reduced in neurons exposed 
to NMDARP-71 antisense oligonucleotide 
Fluorescence ratio imaging of the calcium indicator dye fura- 
was used to measure intracellular free calcium levels in hip- 
pocampal neurons. Changes in intracellular calcium levels fol- 
lowing exposure to NMDA were examined in neurons that had 
been exposed to NMDARP-7 1 antisense or sense oligonucleo- 
tides for 20 hr (Figs. 11, 12). In neurons pretreated with 50 PM 
NMDARP-7 1 sense oligonucleotide, NMDA caused a progres- 
sive rise in intracellular calcium levels during a 10 min exposure 
period, levels were elevated two- to fivefold ahove pretreatment 
levels after 10 min of exposure (Fig. 11). In contrast, calcium 
responses were markedly attenuated in cultures pretreated with 
a 50 PM concentration of either of two antisense oligonucleotides 
(Fig. 11). Examples of calcium images in neurons prior to and 
following sequential exposures to NMDA and kainate are shown 
in Figure 12. Whereas neurons treated with NMDARP-7 1 an- 
tisense showed only very small calcium responses to NMDA, 
responses to kainate were much larger, indicating that the effect 
of the oligonucleotides was specific for NMDA responses. 
NMDARP- 71 antisense oligonucleotides protect neurons 
against excitotoxicity 
Cultures that had heen pretreated with NMDARP-7 1 sense or 
antisense oligonucleotides (50 PM) for 20 hr were exposed to 
200 PM NMDA or kainate and neuronal damage was assessed 
6 and 24 hr later. In cultures exposed to sense oligonucleotide, 
NMDA caused the degeneration of approximately 65% of the 
neurons during a 24 hr exposure period (Figs. 13, 14). Excito- 
toxic damage was characterized by neurite fragmentation and 
vacuolation of the cell body. Neurons in cultures pretreated with 
NMDARP-7 1 antisense oligonucleotides were relatively resis- 
tant to NMDA neurotoxicity. 
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Figure 7. NMDARP-71 antisense oligonucleotides reduce NMDARP-71 immunoreactivity in hippocampal neurons: phase-contrast (left) and 
bright-field (right) micrographs of cultures immunostained with an antibody (clone 17G,,C,; see Mattson et al., 1991) to NMDARP-71. Top, 
Culture that had been exposed to NMDARP-7 1 sense DNA (50 PM) for 20 hr. Middle, Culture that had been exposed to NMDARP-7 1 antisense 
(ASl) DNA (50 PM) for 20 hr. Bottom, Culture immunostained with primary antibody that had been preabsorbed with excess NMDARP-7 1 protein 
(see Materials and Methods). 
Interestingly, NMDARP-7 1 antisense oligonucleotide also 
partially protected hippocampal neurons against kainate neu- 
rotoxicity (Fig. 14). Whereas more than 80% of the neurons 
were vulnerable to 50 PM kainate in control cultures, only 60°h 
were vulnerable in cultures pretreated with 50 PM NMDARP- 
7 1 AS 1. These data suggested that the NMDA receptor may 
participate in the neurotoxicity caused by kainate as has been 
previously suggested (cf. Sucher et al., 1991). Consistent with 
this possibility, we found that the NMDA receptor antagonist 
APV greatly reduced kainate neurotoxicity (Fig. 5). 
Discussion 
Our data indicate that NMDARP-7 1 is present in hippocampal 
neurons, where it plays a role in regulating calcium influx through 
an NMDA-stimulated channel. Selective suppression of the lev- 
els of NMDARP-7 1 using either antisense oligonucleotides or 
bFGF resulted in a marked reduction in the calcium-elevating 
and neurotoxic actions of NMDA. We had previously shown 
that NMDARP-7 1 immunoreactivity localizes to the dendrites 
and cell bodies of cultured hippocampal neurons (Mattson et 

















Figure 8. Time course of reduction in NMDARP-7 1 immunoreactiv- 
ity in hippocampal neurons. Parallel cultures were exposed to no DNA 
(control), NMDARP-7 1 sense (50 PM), NMDARP-7 1 antisense 1 (AS 1, 
50 PM), or NMDARP-7 1 antisense 2 (AS2, 50 PM). Cultures were fixed 
at 12, 20, and 44 hr following treatment. Additional cultures were ex- 
posed for 20 hr to 10 PM NMDARP-7 1 AS 1 (solid circle) or AS2 (open 
circle). Fixed cells were immunostained in parallel using a monoclonal 
antibody to NMDARP-71. Neuronal staining intensities were scored 
on a relative scale (0, no staining; I, light; 2, moderate; 3, heavy). Values 
represent the mean and SEM of determinations made in four separate 
cultures (100 neurons scored/culture). The overall reduction in 
NMDARP-7 1 immunoreactivity in antisense-treated cultures was high- 
ly significant (control vs AS 1, t = 7.1, p < 0.000 1; control vs AS2, t = 
6.5, p i 0.0001; sense vs ASl, t = 8.4, p c 0.0001; sense vs AS2, t = 
6.7, p < 0.0001). 
al., 1991) and hippocampal neurons in viva (Eaton et al., 1990). 
Neurons that expressed high levels of NMDARP-7 1 were par- 
ticularly vulnerable to glutamate neurotoxicity, and a polyclonal 
antibody to NMDARP-7 1 prevented NMDA neurotoxicity 
(Mattson et al., 199 1). In addition, data obtained in cerebellar 
granule cell cultures indicate that the expression of NMDARP- 
7 1 is well correlated with the development of enhanced granule 
cell sensitivity to NMDA and with depolarization-induced neu- 
Figure 9. Levels of NMDARP-71 detected by Western blot analysis 
are reduced in hippocampal cultures exposed to antisense oligonucleo- 
tides. Parallel cultures were left untreated (a) or were exposed to 50 PM 
NMDARP-7 1 sense (b), NMDARP-7 1 AS1 (c), or NMDARP-7 1 AS2 
(d) for 22 hr. Protein was separated by polyactylamide gel electropho- 
resis (50 pg of solubilized protein/lane), transferred to nitrocellulose, 
and immunoblotted using a monoclonal antibody to NMDARP-7 1. The 
blots were subsequently analyzed by image analysis and densitometry. 
The densitometric values are expressed as percentage of the control. 
/ 
Figure 10. Time course of reduction in NMDARP-7 1 mRNA levels 
in cultures exposed to NMDARP-7 1 antisense oligonucleotide. Parallel 
hippocampal cell cultures were treated for 20 hr with NMDARP-71 
sense oligonucleotide (control, 50 PM) or with 50 PM NMDARP-7 1 AS 1 
for 12 or 20 hr, and mRNA levels were quantified by densitometric 
analysis of the 1.8 kb RNA species on Northern blots probed with the 
32P-labeled Pstl fragment of pGBA-2. Densitometric values are ex- 
pressed as percentage of control (i.e., the sense oligonucleotide-treated 
culture). 
ronal survival (Van der Valk et al., 1991; Balazs et al., 1992). 
Protein reconstitution studies demonstrated that while 
NMDARP-7 1 alone is not sufficient to form a functional NMDA 
receptor, it can associate with three additional proteins to form 
functional NMDA-activated ion channels and that the activa- 
tion of this channel by glutamate or NMDA is blocked by pre- 
treatment of the proteins with polyclonal antibodies to 
NMDARP-71 (Kumar et al., 1991; Ly and Michaelis, 1991; 
Minami et al., 1991). We have not tested preparations of the 
hetero-oligomeric complex of NMDA receptor proteins for ion 
Time (min) 
Figure II. NMDA-induced elevations in intraneuronal free calcium 
levels are reduced in neurons pretreated with NMDARP-7 1 antisense 
oligonucleotides. Parallel cultures were exposed to 50 PM NMDARP- 
7 1 sense, AS 1 or AS2 for 20 hr. Calcium measurements were made in 
the same neurons (n = 14-23) prior to and 5 and 10 min following 
exposure to 200 PM NMDA. Values represent the mean and SEM. The 
effect of AS1 and AS2 on the NMDA response (compared to sense- 
treated neurons) was highly significant at both the 5 min (sense vs AS 1, 
t = 7.8, p < 0.0001; sense vs AS2, t = 7.5, p < 0.0001) and 10 min 
(sense vs ASl, t = 9.3, p < 0.0001; sense vs AS2, t = 8.5, p c 0.0001) 
time points (paired Student’s t test). 
Figure 12. Calcium responses to NMDA are selectively reduced in hippocampal neurons exposed to NMDARP-7 1 antisense oligonucleotides. 
Fluorescence ratio images of the calcium indicator dye firm-2 in cultured hippocampal neurons are depicted in pseudocolor according the calcium 
concentration scale shown. Top panels, A field of neurons in culture that had been exposed for 20 hr to 50 PM NMDARP-7 1 sense oligonucleotide 
is shown prior to treatment (left), 5 min following exposure to 200 PM NMDA (middle), and 5 min following a subsequent exposure to 200 PM 
kainate (right). Middle panels, Neurons that had been exposed for 20 hr to 50 PM NMDARP-7 1 antisense oligonucleotide (AS2) are shown prior 
to treatment (left), 5 min following exposure to 200 PM NMDA (middle), and 5 min following exposure to 200 LIM kainate (right). Bottom panels, 
Neurons that had been exposed for 20 hr to 50 PM NMDARP-7 1 antisense oligonucleotide (AS 1) are shown prior to treatment (left), 5 min following 
exposure to 200 PM NMDA (middle), and 5 min following exposure to 200 PM kainate (right). Note that calcium responses toNMDA are greatly 
reduced in the cultures pretreated with NMDARP-7 1 antisense oligonucleotides relative to the culture pretreated with sense oligonucleotide. 
channel activity when only three of the four proteins are recon- required pretreatment with the growth factor for 12-24 hr (Matt- 
stituted, that is, when the 71 kDa NMDARP is absent. By son et al., 1989). It is of interest that the excitoprotective effect 
extension of our observations of inhibition of the function of of bFGF may require mRNA and protein synthesis since the 
this complex produced by antibodies that are specifically re- protective effect is abolished when neurons are incubated in the 
acting with the 7 1 kDa protein, we assume that the absence of presence of either actinomycin D or cycloheximide (Mattson et 
this protein will produce a nonfunctional receptor-ion channel al., 1989). Taken together with the finding that bFGF suppresses 
complex. the expression of NMDARP-7 1, the data are consistent with a 
The time course of suppression of levels of NMDARP-7 1 by scenario in which activation of bFGF receptors leads to pro- 
antisense oligonucleotides and bFGF suggests that NMDARP- duction of proteins involved in the regulation of the gene en- 
7 1 has a half-life of approximately 12-24 hr in cultured coding NMDARP-71. It would be of interest to determine 
hippocampal neurons. This estimation is based upon the ob- whether protein synthesis is required for the suppressive effect 
servation that a single exposure of cultures to NMDARP-71 of bFGF on NMDARP-7 1 levels. 
antisense resulted in a transient reduction in NMDARP-7 1 lev- Hippocampal neurons exposed to antisense oligonucleotides 
els such that levels were markedly reduced after 12-24 hr of to NMDARP-7 1 were protected against NMDA neurotoxicity. 
exposure and then recovered by 48 hr of exposure. In addition, These results demonstrate a role for this NMDARP-71 in ex- 
levels of NMDARP-71 immunoreactivity were markedly re- citotoxicity. Our data also showed that NMDARP-7 1 mediates 
duced after 12-24 hr of exposure to bFGF. These data are con- calcium influx caused by glutamate and NMDA. It is possible 
sistent with our previous study in which we showed that the that the effects of the antisense oligonucleotides were produced 
neuroprotective effect of bFGF against glutamate neurotoxicity through suppression of the expression of NMDARP-7 1 and a 
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Figure 13. Effects ofNMDARP antisense oligonucleotides on NMDARP-7 1 immunoreactivity and vulnerability to NMDA neurotoxicity. Cultures 
were exposed to 50 FM NMDARP-71 sense or antisense oligonucleotides for 20 hr. The cells were then exposed to 200 PM NMDA for 6 hr, at 
which time they were fixed and immunostained with NMDARP-7 1 antibody. Phase-contrast (left) and corresponding bright-field (right) micrographs 
are shown. Note that NMDA caused egeneration of the majority of neurons pretreated with sense oligonucleotide (upper lefi); these neurons 
stained intensely with the NMDARP-71 antibody (upper right). In contrast, the majority of neurons in cultures pretreated with NMDARP-71 
antisense were resistant o NMDA toxicity (lower left) and stained lightly with the NMDARP-71 antibody (lower right). 
subsequent diminution of the expression of other glutamate 
receptor proteins. However, NMDARP-7 1 antisense oligonu- 
cleotides did not reduce levels of GluR 1 or of NMDAR 1 mRNA. 
In additional studies, we have found that a GluRl antisense 
oligonucleotide significantly reduced neuronal damage caused 
by kainate, but did not protect neurons against NMDA neu- 
rotoxicity (M. P. Mattson, unpublished observations). Thus, 
antisense technology may prove valuable in defining roles for 
different glutamate receptor proteins in physiological and patho- 
physiological processes. 
Whereas NMDARP-7 1 antisense oligonucleotides caused a 
marked reduction in levels of the 7 1 kDa protein, they caused 
a more moderate reduction in levels of NMDARP-7 1 mRNA. 
The suppression of NMDARP-71 mRNA was specific for the 
antisense oligonucleotides since sense oligonucleotide did not 
reduce mRNA levels. Although the mechanisms whereby an- 
tisense oligonucleotides reduce protein levels are not completely 
understood, data suggest hat the oligonucleotides can enhance 
degradation of mRNA and/or block translation without en- 
hancing mRNA degradation (Colman, 1990). Our data are con- 
sistent with effects of NMDARP-7 1 antisense oligonucleotides 
on both the level of NMDARP-71 mRNA and blockade of 
translation from extant NMDARP-71 mRNA. The data indi- 
cate that the suppression of NMDARP-7 1 mRNA and protein 
by bFGF was apparently due to a selective effect on this protein 
in neurons. Thus, NMDARP-71 mRNA levels were reduced 
within 24 hr of exposure to bFGF and continued to decline 
through 96 hr of exposure. In contrast, levels of GluRl mRNA 
were not reduced by bFGF. Western blot analysis showed a 
clear reduction in NMDARP-71 levels in bFGF-treated cul- 
tures, whereas EGF and NGF did not reduce NMDARP-71 
levels. Immunocytochemical analysis confirmed the Western 
blot results. 
Previous studies indicated that neuroprotective action of bFGF 
in hippocampal cell cultures is due to a direct action on neurons 
(Mattson and Rychlik, 1990; Cheng and Mattson, 199 1). How- 
ever, since bFGF is a mitogen for astrocytes, it was possible 
that an increase in astrocyte numbers might have contributed 
to the apparent reduction in NMDARP-71 levels in bFGF- 
treated cultures. However, several findings argue against the 
latter possibility, including the following: levels of NMDARP- 
7 1 were clearly reduced in neurons as shown by immunocyto- 
chemical analysis; levels of NMDARP-7 1 protein were not re- 
duced in EGF-treated cultures despite the fact that EGF is a 
potent mitogen for astrocytes (Han et al., 1992); astrocytes rep- 
resented only approximately 20% of the cells in cultures incu- 
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Figure 14. Vulnerability to excitotoxicity is reduced in hippocampal 
cultures pretreated with antisense oligonucleotides to the NMDARP- 
7 1. Parallel cultures were pretreated for 20 hr with 50 WM NMDARP- 
71 AS1 (NMDA+ASl, kainate+ASI) or 50 PM NMDARP-71 sense 
oligonucleotide (NMDA, kainate) and were then exposed to 200 PM 
NMDA or 200 PM kainate. Neuronal survival was determined at 6 and 
24 hr following exposure to the EAAs. Values represent the mean and 
SEM of determinations made in four separate cultures. Values for cul- 
tures pretreated with NMDARP AS1 or NMDARP AS2 were signifi- 
cant@ greater than values for control cultures or cultures exposed to 
NMDARP sense at both the 6 hr (NMDA vs NMDA+ASl. t = 5.8. n 
< 0.01; kainate vs kainate+ASl, i= 5.3, p < 0.02) and 24 hr (NMDA 
vs NMDA+ASl, t = 10.8, p < 0.002; kainate vs kainate+ASl, t = 
5.5, p < 0.02) time points (paired Student’s t tests). 
bated in serum-containing cultures and less than 2% of cells in 
cultures maintained in serum-free medium; the reduction in 
NMDARP-7 1 mRNA and protein levels occurred within 24 hr 
of exposure to bFGF, a time period too short to allow significant 
astrocyte proliferation. In addition, bFGF did not affect astro- 
cyte numbers significantly during a 48 hr exposure period in 
culture medium lacking serum, but nevertheless reduced 
NMDARP-71 levels. Finally, since GluRl levels were not al- 
tered following treatment with bFGF, it is unlikely that sub- 
stantial proliferation of hippocampal astrocytes had occurred. 
Several observations suggest that the suppressive action of 
bFGF on the NMDARP-71 mRNA and protein levels dem- 
onstrated in the present study may have relevance to the intact 
developing and adult brain. First, bFGF has been shown to 
promote the survival and outgrowth of neurons from many 
brain regions including the hippocampus (Morrison et al., 1986; 
Walicke et al., 1986; Mattson et al., 1989). Second, glutamate 
can inhibit dendritic growth cones and cause dendritic regression 
in hippocampal neurons, and these effects of glutamate can be 
prevented by bFGF (Mattson et al., 1989). Third, bFGF can 
protect central neurons against EAA neurotoxicity (Mattson et 
al., 1989; present results), and hypoglycemic damage that in- 
volves NMDA receptor activation (Cheng and Mattson, 199 1). 
Fourth, bFGF can provide trophic support to central neurons 
in the adult brain in viva (Anderson et al., 1988). Fifth, bFGF 
can protect hippocampal neurons against ischemic damage in 
vivo (Berlove et al., 1991). Furthermore, FGF receptors have 
been localized to a large number of neuronal populations in the 
brain including hippocampal neurons (Wanaka et al., 1990; 
Cheng and Mattson, 199 1). Our data indicate that one mech- 
anism whereby bFGF might influence neuronal plasticity and 
survival is by suppressing the expression of an NMDA receptor. 
We recently reported that bFGF prevents the loss of calcium 
homeostasis that normally mediates hypoglycemic excitotoxic 
damage (Cheng and Mattson, 199 1). The present data provide 
an explanation for this calcium-stabilizing action of bFGF. That 
is, by reducing the expression of an NMDA receptor, bFGF 
presumably reduces calcium influx and therefore prevents the 
sustained elevations in intracellular calcium that normally me- 
diate excitotoxicity. 
The suppressive effect of bFGF on the expression of 
NMDARP-7 1 was specific for this growth factor. NGF and EGF 
did not reduce NMDARP-7 1 levels. These data are consistent 
with our previous findings that NGF did not protect hippocam- 
pal neurons against glutamate neurotoxicity (Mattson et al., 
1989), and that EGF did not protect rat hippocampal or human 
cortical neurons against hypoglycemic damage that is NMDA 
receptor mediated (Cheng and Mattson, 1991). On the other 
hand, NGF was reported to protect hippocampal neurons against 
ischemic damage in vivo (Shigeno et al., 1991) and against hy- 
poglycemic damage in vitro (Cheng and Mattson, 199 1). It there- 
fore appears to be the case that NGF and bFGF differ in their 
mechanisms of action. The suppressive effect of bFGF on 
NMDARP-7 1 was specific for this type of EAA receptor since 
GluRl mRNA levels (i.e., the mRNA for the kainate/AMPA 
receptors) were not decreased by bFGF. Since reduction of ex- 
pression of NMDARP-71 protected neurons against NMDA- 
induced cell damage, we conclude that the neuroprotective effect 
of bFGF was due in part to suppression of expression of 
NMDARP-7 1. Whether bFGF and other neuroprotective growth 
factors including NGF (Cheng and Mattson, 1991) or the in- 
sulin-like growth factors (Cheng and Mattson, 1992b) affect the 
expression of other EAA receptors remains to be established. 
The NMDA receptor probably plays an important role in a 
variety of neurodegenerative conditions including stroke, epi- 
lepsy, Alzheimer’s disease, Huntington’s disease, and Parkin- 
son’s disease (Sloviter, 1987; Choi, 1988; Greenamyre and 
Young, 1989; Graham et al., 1990; Otto and Unsicker, 1990; 
Mattson, 1992). Growth factors have also been proposed to play 
roles in each of these disorders (Appel, 1986; Hefti et al., 1989). 
The increasing number of reports of neuron-damaging effects 
of NMDA receptor activation, and neuroprotective effects of 
growth factors (NGF and bFGF in particular), in animal and 
cell culture models of neurodegenerative disorders (see intro- 
ductory remarks) strongly suggests that the mechanism of neu- 
roprotective action of bFGF documented in the present study 
may have relevance to these diseases. Work is now in progress 
to determine whether bFGF influences the expression of 
NMDARP-7 1 in vivo. If a reduction in expression of NMDARP- 
7 1 and resultant protection against excitotoxicity by bFGF also 
occur in humans, then this growth factor may be potentially 
useful in preventing the neuronal damage in the myriad of dis- 
orders that involve NMDA receptors. Clearly, a better under- 
standing of the neuroprotective mechanism of action of bFGF 
may provide information valuable in developing preventative 
and therapeutic strategies for these diseases. 
Although the present study did not directly examine the effects 
of bFGF on processes of neural plasticity such as neurite out- 
growth, synaptogenesis, and LTP, it is certainly worth consid- 
ering the implications of the present findings for these NMDA 
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receptor-mediated processes. Data from an increasing number 
of laboratories have demonstrated roles for EAA receptors in 
general, and the NMDA receptor in particular, in the devel- 
opment of neural circuits. For example, EAA receptors regulate 
neurite outgrowth in hippocampal neurons (Mattson et al., 1988a) 
and promote survival of cerebellar neurons (Balazs et al., 1988). 
The EAA receptors apparently play a major role in the process 
of synapse formation in many brain regions including the visual 
system (Kleinschmidt et al., 1987; Cline et al., 1990) and hip- 
pocampus (Mattson et al., 1988b). In the hippocampus, gluta- 
mate released from axons may activate EAA receptors on den- 
dritic targets, stabilize their outgrowth, and thereby promote 
synaptogenesis (Mattson et al., 1988b; Mattson and Hauser, 
1991). Since bFGF suppressed the expression of the NMDA 
receptor in the embryonic hippocampal neurons in the present 
study, it is reasonable to consider that bFGF might play an 
important role in regulating synaptogenesis in the hippocampus. 
At the mature synapse, NMDA receptors are clearly involved 
in LTP (Collingridge and Bliss, 1987). Previous data suggested 
that growth factors may play roles in processes such as learning 
and memory. For example, Sastry and coworkers have shown 
that NGF and other unidentified proteins can modify LTP in 
the hippocampus (Sastry et al., 1988; Xie et al., 1991). The 
present data provide evidence that bFGF can influence a trans- 
mitter receptor believed to play a central role in the postsynaptic 
calcium influx involved in LTP (Malenka et al., 1988). The 
precise consequences of such an action of bFGF in the context 
of circuits involving many neurons are not clear, and may be 
quite complex. 
Receptors for the EAAs may also be involved in the process 
of natural cell death during development (Mattson and Hauser, 
199 1; Oppenheim, 199 1). It has been recognized for some time 
that growth factors play a role in regulating both cell numbers 
and synaptic connections in developing neural circuits (Purves, 
1986). Neural activity also plays a prominent role in shaping 
neural circuitry (Frank, 1987). Interactions between activity- 
regulating neurotransmitter systems and growth factor systems 
have been demonstrated (Landis, 1990). For example, seizure 
activity increases the expression of NGF in hippocampal neu- 
rons (Gall and Isackson, 1989). The present data provide a direct 
demonstration of regulation of the expression of a neurotrans- 
mitter receptor by a growth factor. We propose that the regu- 
lation of neurotransmitter receptors by target-derived growth 
factors may provide a feedback mechanism to “adjust” activity 
in the involved neural circuits and modify connections adap- 
tively. In the case of the NMDA receptor, a reduction in its 
level by bFGF may be at least part of the mechanism for de- 
termining which neurons live during development. The latter 
possibility is consistent with the “trophic theory” of neural con- 
nections (Purves, 1986) in that the availability of target-derived 
trophic factor plays an important role in determining which 
neurons live and which die. Reciprocal interactions between 
neurotransmitter and growth factor systems may provide a fun- 
damental mechanism of regulating synaptic connections and 
neuronal survival. 
If bFGF does play a role in regulating NMDA receptor ex- 
pression in viva, then it is important to identify the cellular 
sources of bFGF that are important in this process. bFGF is 
believed to be produced by both neurons and glia in vivo (Pett- 
man et al., 1986; Ferrara et al., 1988; Mattson and Rychlik, 
1990). We previously found that neurons contacting astrocytes 
were protected against glutamate neurotoxicity, and that bFGF 
antibodies abolished the excitoprotective effect of astrocytes 
(Mattson and Rychlik, 1990). Those data suggested that bFGF 
associated with astrocytes could reduce neuronal vulnerability 
to EAAs. In the present study, we found that levels of NMDARP- 
7 1 immunoreactivity in neurons contacting astrocytes were low- 
er than in neurons not contacting astrocytes. Furthermore, the 
reduced levels of NMDARP-7 1 immunoreactivity correlated 
with reduced vulnerability to glutamate neurotoxicity. These 
data demonstrate that some types of glial cells can influence the 
expression of EAA receptors, and suggest that astrocytes may 
play important neuromodulatory/neuroprotective roles in vivo. 
The involvement of target-derived and glia-derived growth fac- 
tors in regulating processes such as synaptogenesis, LTP, and 
cell death that involve the NMDA receptor clearly merits further 
study. 
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